In-House Counsel Forum on

Prescription Drug Pricing

Wednesday, January 25, 2006

About

Comply with current pricing regulations prepare for reform defend against new allegations

Public, private and political forces have been focusing on alleged indiscretions in industry pricing practices. Pricing changes under the MMA are now a reality. Pricing changes under Medicaid reform are anticipated shortly. Is your company ready?

This January, the Medicare Drug benefit also known as Medicare Part D, becomes a reality and marks the implementation of the most eagerly awaited reform under the Medicare Modernization Act (MMA). This anticipation, however, is not without anxiety. The implementation of Part D - just as that of Average Sales Price (ASP) a year ago - is causing consternation. Many are confused by seeming contradictions in the Part D regs. Others are anxious to see whether their Part D formulary negotiations have been worth it. There is also fear that without specific guidance from the OIG, Part D may be used as new ammunition to fuel the government's existing onslaught of fraud and abuse investigations relative to pricing.

As we contemplate the as yet undetermined realities of Part D, it's impossible to ignore the existing pricing dilemmas that continue to plague the industry. Recent activity in ongoing pricing actions have led to steep fines, creative government enforcement theories, antitrust scrutiny by the FTC, the building of powerful public and private coalitions, new reimbursement lawsuits under the DOD's TriCare program, and pending national class action status in the existing AWP MDL litigation.

Meanwhile, on the political front, just as you are beginning to adjust to the pricing reforms of the MMA, you must brace for the final federal reforms to the Medicaid program. What changes will these reforms bring? How will they impact and influence other payment systems?

In this unsettled, evolving, and high-risk environment, you must have in-depth knowledge and complete understanding of the latest legal, regulatory, legislative and political developments affecting prescription drug pricing.

This Fourth Annual American Conference Institute In-House Counsel Forum on Government Regulation of Prescription Drug Pricing publication will arm you with the latest information from those at the forefront of Medicare and Medicaid pricing reform, antitrust activity, federal and state investigations and enforcement actions, and private and public litigation. An outstanding faculty of leading attorneys, top federal and state prosecutors, and key government representatives provide insights on:*
  • How key pricing concepts under Medicare, Medicaid, VA and DOD FSS interrelate and influence each other
  • The economic and business impact of ASP pricing in the last year and what this means for your company
    in the next year
  • The complexities of Part D pricing and negotiations
  • What changes to expect under Medicaid reform
  • The proper way to identify institutions that qualify for PHS 34OB pricing
  • How to protect yourself from new fraud and abuse scrutiny under Part D and other novel causes of action


*American Conference Institute cannot guarantee that every presentation will be included in the publication.

Contents & Contributors

About

Comply with current pricing regulations prepare for reform defend against new allegations

Public, private and political forces have been focusing on alleged indiscretions in industry pricing practices. Pricing changes under the MMA are now a reality. Pricing changes under Medicaid reform are anticipated shortly. Is your company ready?

This January, the Medicare Drug benefit also known as Medicare Part D, becomes a reality and marks the implementation of the most eagerly awaited reform under the Medicare Modernization Act (MMA). This anticipation, however, is not without anxiety. The implementation of Part D - just as that of Average Sales Price (ASP) a year ago - is causing consternation. Many are confused by seeming contradictions in the Part D regs. Others are anxious to see whether their Part D formulary negotiations have been worth it. There is also fear that without specific guidance from the OIG, Part D may be used as new ammunition to fuel the government's existing onslaught of fraud and abuse investigations relative to pricing.

As we contemplate the as yet undetermined realities of Part D, it's impossible to ignore the existing pricing dilemmas that continue to plague the industry. Recent activity in ongoing pricing actions have led to steep fines, creative government enforcement theories, antitrust scrutiny by the FTC, the building of powerful public and private coalitions, new reimbursement lawsuits under the DOD's TriCare program, and pending national class action status in the existing AWP MDL litigation.

Meanwhile, on the political front, just as you are beginning to adjust to the pricing reforms of the MMA, you must brace for the final federal reforms to the Medicaid program. What changes will these reforms bring? How will they impact and influence other payment systems?

In this unsettled, evolving, and high-risk environment, you must have in-depth knowledge and complete understanding of the latest legal, regulatory, legislative and political developments affecting prescription drug pricing.

This Fourth Annual American Conference Institute In-House Counsel Forum on Government Regulation of Prescription Drug Pricing publication will arm you with the latest information from those at the forefront of Medicare and Medicaid pricing reform, antitrust activity, federal and state investigations and enforcement actions, and private and public litigation. An outstanding faculty of leading attorneys, top federal and state prosecutors, and key government representatives provide insights on:*
  • How key pricing concepts under Medicare, Medicaid, VA and DOD FSS interrelate and influence each other
  • The economic and business impact of ASP pricing in the last year and what this means for your company
    in the next year
  • The complexities of Part D pricing and negotiations
  • What changes to expect under Medicaid reform
  • The proper way to identify institutions that qualify for PHS 34OB pricing
  • How to protect yourself from new fraud and abuse scrutiny under Part D and other novel causes of action


*American Conference Institute cannot guarantee that every presentation will be included in the publication.

Contents & Contributors


Coming Soon! Email Tina Key, Head Librarian at publications@americanconference.com to be the first to know when this publication becomes available.


DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0